Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors

July 28, 2023 updated by: Kelly E Rentscher, PhD, Medical College of Wisconsin

Accelerated Biological and Phenotypic Aging in Hematopoietic Cell Transplant Survivors: Social Support as a Protective Factor

This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell transplantation (HCT) survivors and can be used to develop biologically informed interventions to improve quality of life and prolong the healthspan of individuals with accelerated aging.

Study Overview

Detailed Description

PRIMARY OBJECTIVES:

I. Examine associations between social support, strain, and isolation and phenotypic aging over the 1-year recovery period.

II. Examine associations between social support, strain, and isolation and biological aging over the 1-year recovery period.

III. Test biological aging as a mediator linking social processes and phenotypic aging.

EXPLORATORY OBJECTIVE:

I. Test sex differences in Aims 1 and 2.

OUTLINE:

Adopting a prospective design, participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives16. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome-wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.

Study Type

Observational

Enrollment (Estimated)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Medical College of Wisconsin Cancer Center Clinical Trials Office
  • Phone Number: 8900 866-680-0505
  • Email: cccto@mcw.edu

Study Locations

    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Recruiting
        • Froedtert Hospital and the Medical College of Wisconsin
        • Contact:
        • Principal Investigator:
          • Kelly Rentscher, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing HCT for hematologic cancers.

Description

Inclusion Criteria:

  • Aged 18 years and older who are competent to give their informed consent.
  • Ability to read, speak, and understand English.
  • Received a hematopoietic cell transplant within the previous 100 days.

Exclusion Criteria:

  • Less then Aged 18 years and older who are competent to give their informed consent.
  • Cannot read, speak, and understand English.
  • Has not received a hematopoietic cell transplant within the previous 100 days.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Supportive care (EAR, questionnaires, biospecimen collection)
Participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
Complete questionnaires
Undergo collection of blood sample
Review of medical records

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Associations between social support, strain, and isolation and phenotypic aging
Time Frame: through study completion, an average of 1 year
Multiple regression models will examine subjective and objective measures of each social process as separate predictors of change in phenotypic aging over the 1-year period, accounting for covariates.
through study completion, an average of 1 year
Associations between social support, strain, and isolation and biological aging
Time Frame: through study completion, an average of 1 year
Raw gene expression data will be quantile-normalized and log2-transformed. Similar to Aim 1, multiple regression models will examine each social process as separate predictors of change in cellular senescence marker p16INK4a over the 1-year period, accounting for covariates. Mixed linear models will examine associations between each social process and deoxyribonucleic acid damage response (DDR) and senescence-associated secretory phenotype (SASP) gene profiles, estimated by maximum likelihood to account for systematic differences across genes by treating them as repeated measurements with an unstructured covariance matrix. Bioinformatics analyses will use regression models to identify genes with > 1.5-fold difference.
through study completion, an average of 1 year
Biological aging as a mediator linking social processes and phenotypic aging
Time Frame: through study completion, an average of 1 year
A regression-based mediation approach will examine biological aging (p16INK4a messenger ribonucleic acid, DDR and SASP composites) as mediating variables in associations between each social process and change in phenotypic aging, using the PROCESS macro for SPSS statistical software.
through study completion, an average of 1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sex differences
Time Frame: through study completion, an average of 1 year
Multiple regression models will examine interactions between social support, strain, and isolation and biological sex as separate predictors of biological (Aim 1) and change in phenotypic (Aim 2) aging, accounting for covariates.
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kelly Rentscher, PhD, Medical College Of Wisconsin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 18, 2021

Primary Completion (Estimated)

May 31, 2025

Study Completion (Estimated)

May 31, 2025

Study Registration Dates

First Submitted

May 10, 2021

First Submitted That Met QC Criteria

May 14, 2021

First Posted (Actual)

May 19, 2021

Study Record Updates

Last Update Posted (Actual)

August 1, 2023

Last Update Submitted That Met QC Criteria

July 28, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 43000 (Other Identifier: Medical College of Wisconsin)
  • NCI-2021-02616 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • K01AG065485 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm

Clinical Trials on Questionnaire Administration

3
Subscribe